BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Moshkovska T, Mayberry J. Duration of treatment with 5-aminosalicylic acid compounds. World J Gastroenterol 2007; 13(32): 4310-4315 [PMID: 17708602 DOI: 10.3748/wjg.v13.i32.4310]
URL: https://www.wjgnet.com/1007-9327/full/v13/i32/4310.htm
Number Citing Articles
1
T. MOSHKOVSKA, M. A. STONE, J. CLATWORTHY, R. M. SMITH, J. BANKART, R. BAKER, J. WANG, R. HORNE, J. F. MAYBERRY. An investigation of medication adherence to 5‐aminosalicylic acid therapy in patients with ulcerative colitis, using self‐report and urinary drug excretion measurementsAlimentary Pharmacology & Therapeutics 2009; 30(11-12): 1118 doi: 10.1111/j.1365-2036.2009.04152.x
2
Reena Khanna, Brian G Feagan. Ustekinumab for the Treatment of Crohn‘s DiseaseImmunotherapy 2013; 5(8): 803 doi: 10.2217/imt.13.81
3
Reena Khanna, John K. Marshall. Crohn's Disease and Ulcerative Colitis2017; : 389 doi: 10.1007/978-3-319-33703-6_38
4
H. Mayberry, T. Moshkovska, J. F. Mayberry. Co-prescribing azathiopurine or 6-mercaptopurine and 5-aminosalicylate compounds in ulcerative colitisInflammatory Bowel Diseases 2009; 15(2): 190 doi: 10.1002/ibd.20750
5
Ryan C Ungaro, Harisha Kadali, Wenwen Zhang, Shashi Adsul, Walter Reinisch. Impact of Concomitant 5-Aminosalicylic Acid Therapy on Vedolizumab Efficacy and Safety in Inflammatory Bowel Disease: Post Hoc Analyses of Clinical Trial DataJournal of Crohn's and Colitis 2023; 17(12): 1949 doi: 10.1093/ecco-jcc/jjad113
6
Lisa J. Herrinton, Liyan Liu, Bruce Fireman, James D. Lewis, James E. Allison, Nicole Flowers, Susan Hutfless, Fernando S. Velayos, Oren Abramson, Andrea Altschuler, Geraldine S. Perry. Time Trends in Therapies and Outcomes for Adult Inflammatory Bowel Disease, Northern California, 1998–2005Gastroenterology 2009; 137(2): 502 doi: 10.1053/j.gastro.2009.04.063
7
Affifa Farrukh, John F Mayberry. Surveillance for colorectal cancer and chemoprevention in ulcerative and Crohn's colitis: The need for clinical strategies to increase effectivenessJGH Open 2019; 3(5): 370 doi: 10.1002/jgh3.12173
8
Zunwu Zhang, Hugh Kennedy. Ulcerative colitis: current medical therapy and strategies for improving medication adherenceEuropean Journal of Gastroenterology & Hepatology 2009; 21(1): 1 doi: 10.1097/MEG.0b013e32830bfb88
9
Reena Khanna, John K. Marshall. Crohn's Disease and Ulcerative Colitis2012; : 453 doi: 10.1007/978-1-4614-0998-4_36
10
Hiroaki Ito, Shigeru Furuta, Hidetaka Sasaki, Toyomitsu Yoshida, Yuichi Takano, Toshifumi Hibi. Pharmacokinetics and safety of single and multiple doses of Asacol tablets in Japanese healthy volunteersAdvances in Therapy 2009; 26(8): 749 doi: 10.1007/s12325-009-0059-9
11
Stefan Schreiber, Michael A Kamm, Gary R Lichtenstein. Mesalamine with MMX™ technology for the treatment of ulcerative colitisExpert Review of Gastroenterology & Hepatology 2008; 2(3): 299 doi: 10.1586/17474124.2.3.299
12
Anita Annaházi, Tamás Molnár. Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug WithdrawalGastroenterology Research and Practice 2015; 2015: 1 doi: 10.1155/2015/832395